Loading...
Triplet therapy with bortezomib, lenalidomide, and dexamethasone (VRd), followed by autologous stem-cell transplant (ASCT) and lenalidomide maintenance is a standard of care for transplant-eligible myeloma patients. Investigators now report an industry-sponsored, multicenter, phase 3 trial comparing VRd to VRd plus the anti-CD38 antibody daratumumab (D-VRd) administered subcutaneously (1800 mg) with induction (4 cycles), post-ASCT consolidation (2 cycles), and lenalidomide maintenance therapy until disease progression.
A total of 709 transplant-eligible patients aged 18–70 years were randomized; 9 (1.3%) were Black and 10 (1.4%) were Asian. At a median follow-up of 48 months, the primary endpoint — progression-free survival (PFS) — was signi…